<DOC>
	<DOCNO>NCT00966251</DOCNO>
	<brief_summary>The objective pilot study evaluate safety , tolerability activity monoclonal antibody CT-011 administer intravenously patient Primary Hepatocellular Carcinoma .</brief_summary>
	<brief_title>Safety Tolerability Study Monoclonal Antibody CT-011 Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subjects age 18 year , gender . 2 . Histologically cytologically confirm Primary Hepatocellular Carcinoma ( HCC ) 3 . No fibrolamellar subtype HCC 4 . Not eligible systemic antineoplastic treatment approve HCC 5 . Not eligible Transarterial chemoembolization ( TACE ) . 6 . No 1 prior systemic therapy . Previous TACE Radiofrequency ablation ( RFA ) use HCC , permit . 7 . Not candidate curative surgical resection liver transplantation 8 . Measurable disease define identification least 1 measurable lesion MRI use RECIST criterion . Tumor area TACE RFA must enlarge postprocedure consider measurable disease . 9 . Alphafetoprotein ( AFP ) great upper limit normal ( ULN ) 10 . Child 's Pugh classification A 11 . ECOG performance status 01 1 . Patients progress liver failure . 2 . No core biopsy within past 7 day 3 . Patients eligible Transarterial Chemoembolization ( TACE ) 4 . Patients concurrent antineoplastic therapy ( include interferon ) 5 . Patients receive systemic antineoplastic therapy approve treatment HCC . 6 . Patients concurrent steroid , allow routine antiemetic , inhale steroid 7 . Presence metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Primary Hepatocellular Carcinoma</keyword>
</DOC>